Scribe Therapeutics Inc.
SCTX
Positions held
Your positionsSCTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $364.06M | Enterprise value | $484.67M | Trailing P/E | — | Forward P/E | -5.32 |
| PEG | — | Price / book | -0.29 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | -60.8% | Earnings growth | — | Gross margin | -53.3% | Operating margin | -4.9% |
| Profit margin | -97.0% | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | 0.57 | Free cash flow | — | Analyst recommendation | none | Mean target | $57.00 |
| 52w high | $39.60 | 52w low | $13.50 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $1.9M | $2.2M | $4.9M | $17.1M |
| Op margin | -489.8% | -556.5% | -237.4% | -32.4% |
| Net income | -$6.5M | -$17.3M | -$9.9M | -$3.4M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$9.4M | -$12.4M | -$11.6M | -$5.6M |
- Revenue -14% vs prior quarter ($1.9M vs $2.2M).
- Operating margin expanded to -489.8%.
Yearly (6y)
| 2025 | 2024 | |
|---|---|---|
| Revenue | $51.2M | $27.4M |
| Op margin | -50.9% | -156.2% |
| Net income | -$21.8M | -$47.8M |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$26.1M | -$42.8M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · Cathie Wood Makes $64 Million Bet on Two Stocks
2026-09-22 · Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
2026-09-17 · Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
2026-09-02 · Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-09-01 · Scribe Therapeutics to Participate in Upcoming Investor Conferences
2026-08-31 · Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
2026-08-24 · Top Premarket Gainers
2026-08-18 · Norwegian Cruise downgrade, Duolingo upgraded: Wall Street's top analyst calls
2026-07-30 · Scribe’s Genetic Editing Aims to Prevent Heart Attacks
2026-07-24 · Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
2026-07-24 · Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
Price (daily)
Full chart · RSI · MACD · patterns